MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Cancer Treatment and Pharmacology
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,351 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,351 works in the cohort · of 4,299,418page 1 of 28

Labels cover 6 of 1,351 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,351 of 1,351 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Harry D. Bear, Gong Tang, Priya Rastogi, Charles E. Geyer, André Robidoux, James N. Atkins +14 more
2012· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
469
citations
afffundno abstractunlabeled
The battle of “nano” paclitaxel
Alexandros Marios Sofias, Michael Dunne, Gert Storm, Christine Allen
2017· review· en· Advanced Drug Delivery Reviews· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
397
citations
afffundunlabeled
Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
Margot J. Burnell, Mark N. Levine, Judith‐Anne W. Chapman, Vivien Bramwell, Karen A. Gelmon, Barbara Walley +8 more
2009· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · research_integrity
152
citations
aboutno affunlabeled
Physicians' Cancer Chemotherapy Drug Manual 2001
Ellen F. Manzullo, Roger W. Anderson
2002· article· en· Annals of Internal Medicine· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
137
citations
affunlabeled
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer
Christine E. Swenson, Lois E. Bolcsak, Gerald Batist, Troy H. Guthrie, Katherine H. R. Tkaczuk, Harold Boxenbaum +4 more
2003· article· en· Anti-Cancer Drugs· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
115
citations
next →

How this was built: Screen · Findings · About